Mackenzie Financial
ONCT

Mackenzie Financial’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Mackenzie Financial’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-997
Closed -$5.99K – 1611
2023
Q3 		$5.99K Hold
997
– – ﹤0.01% 1464
2023
Q2 		$7.09K Hold
997
– – ﹤0.01% 1503
2023
Q1 		$15.7K Hold
997
– – ﹤0.01% 1488
2022
Q4 		$19.9K Hold
997
– – ﹤0.01% 1401
2022
Q3 		$18K Hold
997
– – ﹤0.01% 1410
2022
Q2 		$22K Buy
+997
New +$22.2K ﹤0.01% 1438

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Mackenzie Financial's ONCT Position: Q4 2023 in Review

Mackenzie Financial sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 997 shares — an estimated $5.99K sold.

Mackenzie Financial first reported a position in ONCT in Q2 2022 and held it in 6 quarters. The position peaked at $22K in Q2 2022. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

  • Mackenzie Financial reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Mackenzie Financial sold 997 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5.99K.
  • Mackenzie Financial first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Mackenzie Financial's Oncternal Therapeutics, Inc. Common Stock position peaked at $22K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Mackenzie Financial's 13F filing for Q4 2023, filed 30 Jan 2024.